Caeli Vascular

Caeli Vascular is an early-stage medical device innovator targeting the significant clinical and economic burden of venous thromboembolic disease, specifically large-volume deep vein thrombosis (DVT). The company has developed a patented, multi-modal technology platform intended to enable physicians to perform more complete and safer clot removal across a wider disease spectrum. Founded by a team of entrepreneurs and surgeons from Washington University in St. Louis, Caeli is positioned to enter a large and underserved market where current endovascular treatment adoption is low due to technological limitations. Its success hinges on clinical validation, regulatory clearance, and commercial execution against established competitors.

Patented Multi-Modal thrombectomy platform designed as a comprehensive therapeutic bundle for safe and complete removal of large-volume venous clots.

Caeli competes in the mechanical thrombectomy market dominated by large public companies like Penumbra, Inari Medical, Boston Scientific, and Medtronic. These competitors have broad product portfolios, strong clinical data, and extensive sales forces. Caeli's strategy is to differentiate by focusing specifically on the technical challenge of large-volume DVT.